Lox C D
Life Sci. 1984 Apr 2;34(14):1357-63. doi: 10.1016/0024-3205(84)90007-9.
Male Sprague-Dawley rats were injected with either a single subcutaneous dose of 75 mg of secobarbital, or once daily injections of 20 mg of secobarbital for 7 days. Plasma was collected prior to treatment and 18 hours later (75 mg) or 8 and 15 days later (20 mg). Plasma was analyzed for the platelet count (PLT), prothrombin time (PT), fibrinogen (FIB), and coagulation factor activities for factors II, V, VII, IX, and X. Treatment with a single subcutaneous injection of 75 mg of secobarbital caused statistically significant alterations in every clotting activity measured whereas 7 days of treatment with 20 mg once daily resulted in only 2 clotting factors being abnormal. These two factors returned to pretreatment levels following 7 days of withdrawal of secobarbital. The data indicates that a single larger dose of secobarbital is more influential on hepatic synthesized clotting factor activity than is longer treatment with a lesser dose.
将75毫克司可巴比妥皮下单剂量注射,或每天一次注射20毫克司可巴比妥,连续注射7天,对雄性斯普拉格 - 道利大鼠进行处理。在处理前以及18小时后(75毫克剂量组)或8天和15天后(20毫克剂量组)采集血浆。对血浆进行血小板计数(PLT)、凝血酶原时间(PT)、纤维蛋白原(FIB)以及凝血因子II、V、VII、IX和X活性的分析。皮下单剂量注射75毫克司可巴比妥处理后,所检测的各项凝血活性均出现了具有统计学意义的改变,而每天一次注射20毫克,连续注射7天,仅导致2种凝血因子异常。在停用司可巴比妥7天后,这两种因子恢复到预处理水平。数据表明,单次较大剂量的司可巴比妥对肝脏合成的凝血因子活性的影响大于较小剂量的长期处理。